SUNDAY, MARCH 21
Arrival and Registration

MONDAY, MARCH 22
Welcome and Keynote Session (Joint)
Helen H. Hobbs, University of Texas Southwestern Medical Center, USA
PNPLA3’s Role in NAFLD
Hashem B. El-Serag, Baylor College of Medicine, USA
Changing Epidemiological Trends in Non-Alcoholic Fatty Liver Disease versus Viral-Associated Hepatobiliary Cancers
Non-Alcoholic Fatty Liver Disease, Liver Inflammation and Fibrogenesis in the Pathogenesis of Hepatobiliary Cancers (Joint)
Lopa Mishra, George Washington University, USA
TGF-beta Signaling in Liver Fibrosis and Hepatocellular Carcinoma
Speaker to be Announced
Short Talks Chosen from Abstracts
The Role of the Microbiome in Hepatobiliary Cancers (X6)
Maria Rescigno, Humanitas University, Italy
The Gut-Liver Axis in Liver Cancer Risk Conditions
Yining Lu, Tsinghua University, China
China’s Innovative Practice on Precision Immunotherapy of Hepatocellular Carcinoma: From Outcome Prediction to New Therapeutic Approaches
Speaker to be Announced
Short Talks Chosen from Abstracts
Genetics of NAFLD (X5)
Elizabeth K. Speliotes, University of Michigan, USA
Use of GWAS to Identify SNPs Associated with NAFLD
Hannele Yki-Järvinen, University of Helsinki, Finland
Effects of Genetic Risk Factors for NAFLD on Hepatic Lipid Metabolism
Noura S. Abul-Husn, Icahn School of Medicine at Mount Sinai, USA
HSD17B13 and Protection from Liver Disease in Diverse Patient Populations
Short Talks Chosen from Abstracts
Poster Session 1

TUESDAY, MARCH 23
Tumor Microenvironment and Hepatobiliary Cancers (X6)
Silvia Afio, Columbia University, USA
The Role of Cancer-Associated Fibroblasts in the Pathogenesis of Hepatobiliary Cancers
Amaia Lujambio, Icahn School of Medicine at Mount Sinai, USA
Mechanisms of Immune Escape in Hepatocellular Carcinoma
Alphonse E. Sirica, Virginia Commonwealth University, USA
The Desmoplastic Reaction in Intrahepatic Cholangiocarcinoma: Molecular Drivers and Prognostic Implications
Gregory J. Gores, Mayo Clinic, USA
Targeting the Tumor Microenvironment for Cholangiocarcinoma Therapy
Short Talks Chosen from Abstracts
Role of Lipids in NAFLD (X5)
Mitchell A. Lazar, Perelman School of Medicine, University of Pennsylvania, USA
Circadian Contributions to NAFLD
Daniel A. Heller, Memorial Sloan Kettering Cancer Center, USA
Lipid Dysregulation in Inflammation, NASH, and Cancer
Catherine Postic, INSERM, Institut Cochin, France
Altered Insulin Signaling and Glucose Toxicity in NAFLD
Tobias C. Walther, Harvard School of Public Health, USA
Lipid Droplet Biology in NAFLD
Short Talks Chosen from Abstracts
Hepatobiliary Cancer Biomarkers (X6)
Yujin Hoshida, UT Southwestern Medical Center, USA
Liver Cancer Risk-Predictive Molecular Biomarkers Specific to Clinico-Epidemiological Contexts
Irene Oi Lin Ng, University of Hong Kong, Hong Kong
Molecular Biomarkers in Hepatocellular Carcinoma
Augusto Villanueva Rodriguez, Icahn School of Medicine at Mount Sinai, USA
Liquid Biopsy in Hepatobiliary Cancers
Short Talks Chosen from Abstracts
NAFLD and CVD (X5)
Speaker to be Announced
Jay D. Horton, University of Texas Southwestern Medical Center, USA
Molecular Mediators of NAFLD and Hyperlipidemia
Henry N. Ginsberg, Columbia University College of Physicians and Surgeons, USA
Loss of Function of TorsinA, an ER Localized AAA ATPase Causes Severe Steatosis with Decreased VLDL Secretion and Abnormal ER Lipid Droplets

* Session Chair † Invited but not yet accepted Program current as of June 20, 2020. Program subject to change. Meal formats are based on meeting venue. For the most up-to-date details, visit https://www.keystonesymposia.org.
Short Talks Chosen from Abstracts

Poster Session 2

**WEDNESDAY, MARCH 24**

Genomic and Epigenomic Heterogeneity in Hepatobiliary Cancers (X6)

Xin Wei Wang, NCI, National Institutes of Health, USA
Causes and Functional Intricacies of Intertumor and Intratumor Heterogeneity in Primary Hepatobiliary Cancers

Jessica Zucman-Rossi, University Paris Descartes-HEGP, France
Molecular Subtypes of Hepatocellular Carcinoma are Related to Specific Tumor Phenotypes

Molecular Subtypes of Hepatocellular Carcinoma are Related to Specific Tumor Phenotypes

Renumathy Dhanasekaran, Stanford University, USA
Complexities of Genetic Heterogeneity in Hepatocellular Carcinoma

Bin Tean Teh, Duke-NUS Medical School, Singapore
Cholangiocarcinoma in Diverse Populations

Short Talks Chosen from Abstracts

Pathways to NASH (X5)

Speaker to be Announced

Mark A. McNiven, Mayo Clinic, USA
Lipid Droplet Formation and Lipophagy in Fatty Liver Disease

Eran Elinav, Weizmann Institute of Science, Israel
Lipid-Associated Macrophages Control Metabolic Homeostasis

Speaker to be Announced

Short Talks Chosen from Abstracts

Emerging Therapies for NASH-I (X5)

Morris J. Birnbaum, Pfizer Inc., USA
DGAT2 Inhibition for NASH

Greg Steinberg, McMaster University, Canada
Cellular Energy Sensors and Metabolism

Short Talks Chosen from Abstracts

"Omics" for Precision Medicine of Hepatobiliary Cancers (X6)

Josep Llovet, Icahn School of Medicine at Mount Sinai, USA
Integrative "Omics" and Precision Medicine for Hepatocellular Carcinoma

Jesper Bøje Andersen, University of Copenhagen, Denmark
Defining Distinct Subtypes of Intrahepatic Cholangiocarcinoma by Molecular Profiling: Diagnostic, Prognostic, and Therapeutic Applications

Robert F. Schwabe, Columbia University, USA
Discovery of Subgroup-Specific HCC Master Regulators by Systems Biology Approaches

Short Talks Chosen from Abstracts

Advances in Molecular and Immune Targeting of Hepatobiliary Cancers (X6)

Bruno Sangro, Clínicas Universidad de Navarra, Spain
Targeted Agent and Immune-Based Therapies for Hepatocellular Carcinoma

Tim F. Greten, NCI, National Institutes of Health, USA
Immunotherapies for Hepatobiliary Cancers: Current Status and Future Perspectives

R. Kate Kelley, University of California, San Francisco, USA
 Developing Clinical Trials of Novel Therapeutic Agents and Treatment Combinations for Intrahepatic Cholangiocarcinoma

Short Talks Chosen from Abstracts

Emerging Therapies for NASH-II (X5)

Kendra K. Bence, Pfizer Inc., USA
Inhibition of Fructose Metabolism for the Treatment of NAFLD

Chuhan Chung, Gilead Sciences, USA
ACC Inhibitors for NASH

Lei Ling, NGM Biopharmaceuticals, USA
Therapeutic FGF19 in Non-Alcoholic Steatohepatitis

Short Talks Chosen from Abstracts

Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (X6)

Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (X5)

**THURSDAY, MARCH 25**

Departure